

4-Amino-2-(*p*-chlorophenyl)-5-methyl-3,4-dihydro-2*H*-1,2,4-triazol-3-oneS. Thamocharan,^a
V. Parthasarathi,^{a*} Jyoti R.
Kavali,^b Bharati Badami^b and
Kurt J. Schenk^c^aDepartment of Physics, Bharathidasan
University, Tiruchirappalli 620 024, India,^bPost-Graduate Department of Studies in
Chemistry, Karnatak University, Dharwad 580
003, India, and ^cInstitut de Cristallographie,
Université de Lausanne, BSP Dorigny, CH-1015
Lausanne, Switzerland

Correspondence e-mail: vpsarati@yahoo.com

Key indicators

Single-crystal X-ray study

T = 293 K

Mean $\sigma(\text{C}-\text{C}) = 0.003 \text{ \AA}$

R factor = 0.042

wR factor = 0.117


Data-to-parameter ratio = 14.2

For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.

In the title compound, $\text{C}_9\text{H}_9\text{ClN}_4\text{O}$, the dihedral angle between the substituted phenyl and triazole rings is $4.86(5)^\circ$. In the crystalline state, the molecules exist as centrosymmetrically related $\text{N}-\text{H}\cdots\text{O}$ hydrogen-bonded dimers.

Comment

Amino-functionalized triazole derivatives serve as starting compounds for heterocyclic syntheses. The triazole moiety possesses many pharmacological properties, *e.g.* antimicrobial (Habib *et al.*, 1997), antiviral (Ergen *et al.*, 1996), anti-HIV-1 (Invidiata *et al.*, 1996), antifungal, antimycobacterial and anticonvulsant (Gülerman *et al.*, 1997). It is also a highly potent eosinophilia inhibitor (Naito *et al.*, 1996) and is used as a fungicide (Crofton, 1996) and a herbicide (Tada *et al.*, 1995). Some triazole derivatives have been evaluated for their antibacterial activity against both Gram-positive and Gram-negative bacteria (Bs *et al.*, 1996). In view of these findings, the structure determination of the title compound, (I), was undertaken.



A perspective view of (I), including the atomic numbering scheme, is shown in Fig. 1. The bond lengths and angles in (I) are unexceptional (Table 1), and comparable with those reported for related structures (Chen *et al.*, 1998; Wang *et al.*, 1998; Thamocharan, Parthasarathi, Sunagar *et al.*, 2003; Thamocharan, Parthasarathi, Hunnur *et al.*, 2003). The sum of bond angles around N41 is 320° , which indicates a pyramidal geometry at N41. The dihedral angle between the substituted phenyl and triazole rings is $4.86(5)^\circ$, while the corresponding angles in the chloro (Thamocharan, Parthasarathi, Sunagar *et al.*, 2003) and bromo (Thamocharan, Parthasarathi, Hunnur *et al.*, 2003) derivatives of triazole are $30.63(9)$ and $8.93(14)^\circ$, respectively. In the crystal structure, centrosymmetrically related molecules form dimers through $\text{N}-\text{H}\cdots\text{O}$ intermolecular hydrogen bonds (Fig. 2) and have a graph-set motif of $R_2^2(10)$ (Table 2) (Bernstein *et al.*, 1995).

Experimental

The title compound was prepared by heating 3-(4-chlorophenyl)-5-methyl-1,3,4-oxadiazolin-2-one with hydrazine hydrate in ethanol. The solid obtained, (I), was crystallized from absolute ethanol (m.p. 458–459 K).

Received 27 May 2003

Accepted 5 June 2003

Online 17 June 2003




Figure 1

A view of (I), showing the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. H atoms are represented by circles of arbitrary radii.




Figure 2

Linkage of molecules into dimers [symmetry codes: (*) $1 - x, 2 - y, 1 - z$; (#) $-x, 2 - y, 1 - z$]. H atoms bonded to C atoms have been omitted for clarity.

Crystal data

$C_9H_9ClN_4O$	$Z = 2$
$M_r = 224.65$	$D_x = 1.492 \text{ Mg m}^{-3}$
Triclinic, $P\bar{1}$	Mo $K\alpha$ radiation
$a = 4.0135 (8) \text{ \AA}$	Cell parameters from 4074 reflections
$b = 11.691 (2) \text{ \AA}$	$\theta = 12.2\text{--}27.9^\circ$
$c = 11.986 (2) \text{ \AA}$	$\mu = 0.36 \text{ mm}^{-1}$
$\alpha = 117.09 (3)^\circ$	$T = 293 (2) \text{ K}$
$\beta = 90.79 (3)^\circ$	Platelet, translucent colourless
$\gamma = 91.89 (3)^\circ$	$0.61 \times 0.30 \times 0.15 \text{ mm}$
$V = 500.17 (16) \text{ \AA}^3$	

Data collection

Stoe IPDS diffractometer
 φ scans OK?
 Absorption correction: none
 4391 measured reflections
 2060 independent reflections
 1807 reflections with $I > 2\sigma(I)$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.042$
 $wR(F^2) = 0.117$
 $S = 1.06$
 2060 reflections
 145 parameters
 H atoms treated by a mixture of independent and constrained refinement

$R_{\text{int}} = 0.024$
 $\theta_{\text{max}} = 27.8^\circ$
 $h = -4 \rightarrow 4$
 $k = -15 \rightarrow 15$
 $l = -15 \rightarrow 15$
 $w = 1/[\sigma^2(F_o^2) + (0.0674P)^2 + 0.0798P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\text{max}} < 0.001$
 $\Delta\rho_{\text{max}} = 0.17 \text{ e \AA}^{-3}$
 $\Delta\rho_{\text{min}} = -0.17 \text{ e \AA}^{-3}$

Table 1

Selected geometric parameters (\AA , $^\circ$).

N1—C5	1.3017 (19)	N4—C5	1.3687 (18)
N1—N2	1.4001 (16)	N4—C3	1.3828 (18)
N2—C3	1.3682 (18)		
C5—N1—N2	104.81 (11)	N4—N41—H412	108 (2)
C3—N2—N1	111.97 (11)	H411—N41—H412	106 (2)
C5—N4—C3	109.34 (12)	N2—C3—N4	102.89 (11)
N4—N41—H411	105.8 (16)	N1—C5—N4	110.99 (13)

Table 2

Hydrogen-bonding geometry (\AA , $^\circ$).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
N41—H411 \cdots O3 ⁱ	0.92 (2)	2.17 (2)	3.043 (3)	159 (2)
N41—H412 \cdots O3 ⁱⁱ	0.84 (3)	2.30 (3)	2.958 (2)	135 (2)

Symmetry codes: (i) $1 - x, 2 - y, 1 - z$; (ii) $-x, 2 - y, 1 - z$.

The amino H atoms were located from a difference Fourier map and refined freely with individual isotropic displacement parameters. The methyl H atoms were constrained to an ideal geometry ($C-H = 0.96 \text{ \AA}$), with $U_{\text{iso}}(H) = 1.5U_{\text{eq}}(C)$, but were allowed to rotate freely about the parent $C-C$ bond. All remaining H atoms were placed in geometrically idealized positions ($C-H = 0.93 \text{ \AA}$) and constrained to ride on their parent atoms with $U_{\text{iso}}(H) = 1.2U_{\text{eq}}(C)$.

Data collection: *IPDS Software Package* (Stoe & Cie, 1997); cell refinement: *IPDS Software Package*; data reduction: *IPDS Software Package*; program(s) used to solve structure: *DIRDIF99* (Beurskens *et al.*, 1999); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *ORTEP-3* (Farrugia, 1997); software used to prepare material for publication: *SHELXL97* and *PLATON* (Spek, 2003).

BB and JRK are grateful to Dr G. S. Puranik, Retired Professor of Organic Chemistry, Karnatak University, Dharwad, for valuable suggestions and encouragement.

References

- Bernstein, J., Davis, R. E., Shimoni, L. & Chang, N.-L. (1995). *Angew. Chem. Int. Ed. Engl.* **34**, 1555–1573.
- Beurskens, P. T., Beurskens, G., de Gelder, R., García-Granda, S., Gould, R. O., Israel, R. & Smits, J. M. M. (1999). *The DIRDIF99 Program System*. Technical Report of the Crystallography Laboratory, University of Nijmegen, The Netherlands.
- Bs, H., Akberali, P. M. & Shivananda, M. K. (1996). *Boll. Chim. Farm.* **135**, 447–451.
- Chen, W., Wang, Z. X., Jian, F. F., Bai, Z. P. & You, X. Z. (1998). *Acta Cryst. C* **54**, 851–852.
- Crofton, K. M. (1996). *Toxicol. Lett.* **84**, 155–159.
- Ergen, C. N., Ulusoy, N., Capan, G., Sains, G. O. & Kiraz, M. (1996). *Arch. Pharm. (Weinheim)*, **329**, 427–430.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Gülerman, N., Rollas, S., Kiraz, M., Ekinci, A. C. & Vidin, A. (1997). *Farmaco*, **52**, 691–695.
- Habib, N. S., Soliman, R., Ashour, F. A. & El-Taiebi, M. (1997). *Pharmazie*, **52**, 844–847.
- Invidiata, F. P., Simoni, D., Scintu, F. & Pinna, N. (1996). *Farmaco*, **51**, 659–664.
- Naito, Y., Akahoshi, F., Takeda, S., Okada, T., Kajii, M., Nishimura, H., Sugiura, M., Fukaya, C. & Kagitani, Y. (1996). *J. Med. Chem.* **39**, 3019–3029.

- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.
- Stoe & Cie (1997). *IPDS Software Package*. Version 2.89. Stoe & Cie GmbH, Darmstadt, Germany.
- Tada, S., Hatano, M., Nakayama, Y., Volrath, S., Guyer, D., Ward, E. & Ohta, D. (1995). *Plant Physiol.* **109**, 153–159.
- Thamotharan, S., Parthasarathi, V., Hunnur, R. K., Badami, B. & Linden, A. (2003). *Acta Cryst.* **E59**, o225–o226.
- Thamotharan, S., Parthasarathi, V., Sunagar, V., Badami, B. & Linden, A. (2003). *Acta Cryst.* **E59**, o75–o76.
- Wang, Z. X., Bai, Z. P., Yang, J. X., Okamoto, K. I. & You, X. Z. (1998). *Acta Cryst.* **C54**, 438–439.